Detrimental immediate and medium-term clinical effects of right ventricular pacing in patients with myocardial fibrosis. by Saunderson, C.E.D. et al.
This is a repository copy of Detrimental immediate and medium-term clinical effects of 
right ventricular pacing in patients with myocardial fibrosis..




Saunderson, C.E.D., Paton, M.F., Brown, L.A.E. et al. (15 more authors) (2021) 
Detrimental immediate and medium-term clinical effects of right ventricular pacing in 






This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Circ Cardiovasc Imaging. 2021;14:e012256. DOI: 10.1161/CIRCIMAGING.120.012256 May 2021 426
Circulation: Cardiovascular Imaging
Christopher E.D.  
Saunderson, MBChB
Maria F. Paton , MSc
Louise A.E. Brown , 
MBChB
John Gierula, PhD
Pei G. Chew , MBChB
Arka Das, MBChB
Anshuman Sengupta, PhD




Eylem Levelt, MBBS, DPhil
Erica Dall’Armellina, MD, 
PhD
Pankaj Garg , PhD
Klaus K. Witte , MD
John P. Greenwood, PhD
Sven Plein, PhD




Key Words: atrioventricular block  
◼ biomarkers ◼ fibrosis ◼ heart failure 
◼ heart ventricles
© 2021 The Authors. Circulation: 
Cardiovascular Imaging is published 
on behalf of the American Heart 
Association, Inc., by Wolters Kluwer 
Health, Inc. This is an open access 
article under the terms of the Creative 
Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
BACKGROUND: Long-term right ventricular (RV) pacing leads to heart 
failure or a decline in left ventricular (LV) function in up to a fifth of 
patients. We aimed to establish whether patients with focal fibrosis 
detected on late gadolinium enhancement cardiovascular magnetic 
resonance (CMR) have deterioration in LV function after RV pacing.
METHODS: We recruited 84 patients with LV ejection fraction ≥40% 
into 2 observational CMR studies. Patients (n=34) with a dual-chamber 
device and preserved atrioventricular conduction underwent CMR in 
2 asynchronous pacing modes (atrial asynchronous and dual-chamber 
asynchronous) to compare intrinsic atrioventricular conduction with 
forced RV pacing. Patients (n=50) with high-grade atrioventricular block 
underwent CMR before and 6 months after pacemaker implantation to 
investigate the medium-term effects of RV pacing.
RESULTS: The key findings were (1) initiation of RV pacing in patients 
with fibrosis, compared with those without, was associated with greater 
immediate changes in both LV end-systolic volume index (5.3±3.5 versus 
2.1±2.4 mL/m2; P<0.01) and LV ejection fraction (−5.7±3.4% versus 
−3.2±2.6%; P=0.02); (2) medium-term RV pacing in patients with fibrosis, 
compared with those without, was associated with greater changes in LV 
end-systolic volume index (8.0±10.4 versus −0.6±7.3 mL/m2; P=0.008) 
and LV ejection fraction (−12.3±7.9% versus −6.7±6.2%; P=0.012); (3) 
patients with fibrosis did not experience an improvement in quality of life, 
biomarkers, or functional class after pacemaker implantation; (4) after 
6 months of RV pacing, 10 of 50 (20%) patients developed LV ejection 
fraction <35% and were eligible for upgrade to cardiac resynchronization 
according to current guidelines. All 10 patients had fibrosis on their 
preimplant baseline scan and were identified by >1.1 g of fibrosis with 
90% sensitivity and 70% specificity.
CONCLUSIONS: Fibrosis detected on CMR is associated with immediate- 
and medium-term deterioration in LV function following RV pacing and 
could be used to identify those at risk of heart failure before pacemaker 
implantation.
Detrimental Immediate- and Medium-Term 
Clinical Effects of Right Ventricular Pacing 
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R
ight ventricular (RV) pacing is an established treat-
ment for symptomatic bradycardia and has been 
shown to normalize life expectancy and improve 
quality of life.1,2 RV apical pacing has the disadvantage 
of inducing electrical and mechanical dyssynchrony, 
which may lead to progressive left ventricular (LV) dys-
function and heart failure.3–5 Up to a fifth of patients 
with a pacemaker for bradycardia will develop heart fail-
ure or have a decline in LV ejection fraction (LVEF) with 
long-term RV pacing.6,7 Alternate strategies such as RV 
septal pacing and pacing avoidance algorithms have 
failed to improve patient-orientated clinical end points.8 
The BLOCK-HF trial (Biventricular Pacing for Atrioven-
tricular Block and Systolic Dysfunction) demonstrated 
improvements in a composite end point of death, heart 
failure hospitalization, and reduction in LV dimensions 
with cardiac resynchronization therapy (CRT) over RV 
pacing in patients with atrioventricular block and an 
LVEF <50%.9 However CRT is associated with a greater 
upfront economic cost, a higher rate of complications, 
and shorter battery longevity than dual-chamber pac-
ing, and its utility in patients with preserved or mildly 
impaired LV function is less established.10–12 There is, 
therefore, a need to improve identification of those at 
risk of decline in LVEF and consequent heart failure af-
ter long-term RV pacing who could benefit from an al-
ternative, personalized upfront pacemaker prescription.
Cardiovascular magnetic resonance (CMR) provides 
an accurate serial assessment of cardiac volumes, evalu-
ation of LV synchronicity, and detection of myocardial 
fibrosis.13 Late gadolinium enhancement (LGE) imaging 
is established for the assessment of myocardial fibrosis 
in a range of cardiovascular conditions. Conventional 
segmented LGE imaging can be a challenge in brady-
cardic patients due to the long duration of breath hold 
required and also in patients with implanted cardiac de-
vices due to off-resonance artifacts.14 Recent advances 
in CMR, and the advent of magnetic resonance imag-
ing (MRI) conditional pacing systems, mean these issues 
can be overcome using free breathing and wideband 
LGE pulse sequences.14
We aimed to establish whether fibrosis detected on 
LGE CMR is associated with greater deterioration in LV 
function following acute and medium-term RV pacing 
by studying 2 separate patient cohorts.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Study 1: Immediate Effects of RV Pacing
Forty-three adult patients (>18 years) with dual-chamber MRI 
conditional pacemakers or secondary prevention implantable 
cardioverter-defibrillators implanted >6 weeks previously were 
recruited from the Leeds General Infirmary Pacemaker Service 
between November 2017 and April 2019. Inclusion in the 
study required a ventricular pacing burden of <5% and the 
presence of sinus rhythm at the most recent device interroga-
tion. Exclusion criteria included any contraindication to CMR, 
pregnancy or breastfeeding, estimated glomerular filtration 
rate <30 mL/min, and severe valvular heart disease. Patients 
underwent ECG and a single multiparametric CMR scan, 
including cine imaging and LGE, in 2 asynchronous pacing 
modes (atrial asynchronous [AOO] and dual-chamber asyn-
chronous [DOO]) at the same base rate to compare intrinsic 
atrioventricular conduction with forced dual-chamber pacing. 
In DOO mode, RV pacing was forced by shortening the paced 
atrioventricular delay and confirmed with a characteristic QRS 
pattern on a surface ECG. Patients with reduced LV function 
(LVEF, <40%) during intrinsic atrioventricular conduction were 
excluded from the final analysis (Figure 1). Ethical approval 
was granted by the Health Research Authority (National 
Research Ethics Service Centre: Yorkshire and Humber REC: 
12/YH/0551 and 18/YH/0168). Written informed consent was 
obtained from all participants.
Study 2: Medium-Term Effects of RV 
Pacing
Sixty-seven unselected consecutive adult patients with 
acquired atrioventricular block scheduled to undergo 
single- or dual-chamber pacemaker implantation were 
prospectively recruited from the Leeds General Infirmary 
between February 2018 and January 2019. Inclusion cri-
teria included class I or IIa indication for a pacemaker due 
to atrioventricular block and an expectation of a high 
requirement for RV pacing.1 Exclusion criteria included a 
prior diagnosis of heart failure or LVEF <40%, recent use of 
temporary pacing system, acute coronary syndrome within 
the last 30 days, severe valvular heart disease, class 1 CRT 
indication, and contraindication to CMR. Since all standard 
CLINICAL PERSPECTIVE
Long-term right ventricular pacing leads to heart 
failure or a decline in left ventricular function in 
up to a fifth of patients. Upfront identification of 
patients at risk of decline in left ventricular ejec-
tion fraction and consequent heart failure after 
long-term right ventricular pacing remains a clini-
cal challenge. This study showed that the short- 
and medium-term detrimental effects on left 
ventricular function during right ventricular pacing 
are most pronounced in patients with myocardial 
fibrosis identified by late gadolinium enhancement 
on cardiovascular magnetic resonance. Myocardial 
fibrosis may represent a risk factor that could be 
used prospectively to identify patients susceptible 
to the detrimental effects of right ventricular pac-
ing. Further work is needed to identify whether 
patients with fibrosis benefit from alternative pac-
ing strategies or medical therapies applied at the 
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pacemaker systems implanted in the Leeds Service are 
MRI conditional, decisions regarding the indication, type 
of device, and device programming were taken by the 
patient’s clinical team. Patients underwent assessment 
including multiparametric CMR with LGE imaging, before 
and 6 months after pacemaker implantation (Figure 1). The 
New York Heart Association functional class and health sta-
tus, using the EuroQoL-5D-3L questionnaire, were assessed 
at baseline and follow-up. ECGs and venous blood sam-
pling were performed before CMR from each patient at 
both visits (Data Supplement). Ethical approval was granted 
by the Health Research Authority (National Research Ethics 
Service Centre: East Midlands REC: 17/EM/0475). Written 
informed consent was obtained from all participants.
Power Calculation
In study 2, an a priori power calculation was performed, to 
detect a clinically meaningful (10 mL) change in LV end-sys-
tolic volume between those with and without LV scar based 
on interstudy SD of 5.4%; a minimum of 7 patients with LV 
fibrosis determined by LGE were required (α, 5%; β, 10%).15 
A sample size of 50 was chosen to allow for a minimum prev-
alence of 14%, which is similar to the prevalence of unrecog-
nized scar in similarly aged populations.16
Device Programming
Before entering the MRI room, patients underwent full device 
interrogation and were programmed into manufacturer-spe-
cific MRI safe mode with tachyarrhythmia therapies disabled 
in patients with implantable cardioverter-defibrillators.
Patients enrolled into study 1 were programmed to both 
AOO and DOO pacing, in a random order, at least 10 bpm 
above their intrinsic heart rate to avoid competition (Figure 1).
In study 2, for the follow-up scan at 6 months, the device 
was programmed to asynchronous pacing at a base rate of 
80 bpm in either ventricular, in patients with a single-cham-
ber pacemaker or in atrial fibrillation, or DOO asynchronous 
pacing modes. In those with a sinus rate above 80 bpm, the 
base rate was programmed to 10 bpm above the intrinsic 
heart rate to avoid competition and ensure sequential atrio-
ventricular pacing.
During the CMR examination, patients were monitored 
using noninvasive blood pressure and vectorcardiogram sig-
nal. A device check was performed immediately after the 
CMR. Device and lead models are available in Table I in the 
Data Supplement.
Cardiovascular Magnetic Resonance
All participants underwent CMR imaging at 1.5T (Ingenia; 
Philips, Best, the Netherlands), which included cine and LGE 
imaging. LGE imaging was optimized using free breathing 
or wideband sequences as required (Data Supplement). All 
scans were performed with a doctor (C.E.D.S.) and a cardiac 
physiologist (M.F.P./J.G.) with expertise in cardiac devices in 
attendance.
Image Analysis
CMR analysis was performed quantitatively offline by a sin-
gle operator (C.E.D.S.) blinded to clinical data and scanning 
Figure 1. Study design and protocol.
AOO indicates atrial asynchronous pacing; AV, atrioventricular; CMR, cardiovascular magnetic resonance; DOO, dual chamber asynchronous pacing; ICD, implant-
able cardioverter defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PM, pacemaker; and 
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order. Analysis was performed using commercially available 
software (Cvi42; Circle Cardiovascular Imaging, Calgary, 
Canada). LV volumes and LVEF were calculated by the sum-
mation-of-discs method.15
LGE images were visually reviewed for the presence or 
absence of LGE by at least 2 observers blinded to clini-
cal data (C.E.D.S./L.A.E.B./S.P./P.P.S.; Figure 2). The pres-
ence of ischemic and nonischemic patterns of myocardial 
fibrosis was assessed according to previously published 
work.17 Semiautomated quantification of LGE was then 
performed using a threshold of 5 SDs of signal intensity 
of the remote myocardium.18 Strain parameters were cal-
culated using feature tracking software (Cvi42) and used 
to determine a mechanical dyssynchrony index (Data 
Supplement).
Biochemical Analysis
NT-proBNP (N-terminal pro-B-type natriuretic peptide) was 
measured with the Advia Centaur system (Siemens Healthcare 
Diagnostics, Camberley, United Kingdom), which quantifies 
NT-proBNP with a range of 35 to 35 000 pg/mL. The intra-
assay coefficient of variation was 5% at a concentration of 
100 to 500 pg/mL.
Statistical Analysis
Statistical analysis was performed using SPSS 25 
(International Business Machines, Armonk, NY). Continuous 
variables are expressed as mean±SD or as median with 
interquartile range and categorical variables, as counts and 
percentages. Normality for continuous variables was tested 
using the Shapiro-Wilk test. For normally distributed vari-
ables, independent samples t testing was used for com-
parisons between groups and paired samples t testing was 
applied for comparisons within groups. For non-normally 
distributed variables, independent samples Mann-Whitney 
U test and the related samples Wilcoxon signed-rank test 
were used as appropriate while comparison of categorical 
variables used the χ2 test. P<0.05 was considered signifi-
cant. Cutoff values of LGE mass at baseline to predict LVEF 
<35% at 6 months were derived from receiver operator 
characteristic curve analysis.
RESULTS
Study 1: Immediate Effects of RV Pacing
During the prospective data collection period, of the 43 
patients recruited, 42 patients underwent assessment, 
and 8 were excluded leaving 34 patients in the final 
analysis (Figure 1).
Fibrosis detected by LGE was present in 18 (53%) 
patients, and differences between those with and 
without LGE are shown in Table  1. The location and 
distribution of myocardial fibrosis detected by CMR 
in study participants is available in Table II in the Data 
Supplement. Patients with fibrosis were older (74.2 ver-
sus 64.2; P=0.008), more frequently had a history of 
myocardial infarction (MI; 56% versus 0%; P<0.001), 
and had greater LV end-diastolic volume index (LVEDVi; 
77.5±13.8 versus 65.6±12.4 mL/m2; P=0.01) and LV 
end-systolic volume index (LVESVi; 37.6±11.4 versus 
29.5±9.8 mL/m2; P=0.03) without a significant dif-
ference in baseline LVEF during intrinsic conduction 
(52.2±8.0% versus 56.0±6.2%; P=0.13).
DOO pacing was associated with an immediate in-
crease in LVESVi when compared with AOO pacing at 
the same heart rate, and this change was greater in 
those with fibrosis than in those without (+5.3±3.5 
versus +2.1±2.4 mL/m2; P=0.005; Table 2; Figure 3). 
No significant change was observed in LVEDVi be-
tween pacing modes in either group. LVEF was lower 
in both groups during DOO compared with AOO pro-
gramming but more so in those with fibrosis compared 
with those without (−5.7±3.4% versus −3.2±2.6%; 
P=0.02). No difference was observed in the intrin-
sic or paced QRS duration between those with and 
without fibroses (P>0.05). Mechanical dyssynchrony 
index increased during DOO pacing, compared with 
AOO pacing, but the change was only statistically 
significant in patients with fibrosis (88.8±21.2 versus 
81.3±17.6 ms; P=0.04).
Figure 2. Late gadolinium imaging in study participants.
Representative short-axis late gadolinium enhancement (LGE) images in 
bradycardic patients before pacemaker implantation (A–C) and in patients 
with implanted pacemakers (D–F). Examples demonstrate the presence 
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Study 2: Medium-Term Effects of RV 
Pacing
Sixty-seven patients were recruited with 54 complet-
ing 6-month follow-up. Four patients were excluded 
(Figure  1), leaving a total of 50 patients (Table  3). 
No adverse events secondary to bradycardia were 
observed during the CMR scan, and imaging was 
feasible in all patients. Fibrosis by LGE imaging was 
present in 31 (62%) patients, and the location and 
distribution of myocardial fibrosis is available in Table 
II in the Data Supplement.
Patients with fibrosis were more often male (90% 
versus 63%; P=0.02) and had a higher prevalence of 
atrial fibrillation (39% versus 10%; P=0.03), previous 
MI (35% versus 0%; P=0.003), and previous coronary 
artery bypass grafting (10% versus 0%; P=0.006). No 
difference was observed in the baseline New York Heart 
Association class between groups. The distribution of 
type and severity of conduction tissue disease was 
not different between those with and without fibrosis 
(Table III in the Data Supplement). All patients except 
one had RV leads placed in the RV apex. Patients with 
fibrosis had higher baseline NT-proBNP (Table 3). Base-
line LVEF was lower in those with fibrosis (55.5±7.9% 
versus 60.2±5.4%; P=0.03).
At 6 months, ventricular pacing burdens were the 
same in patients with and without fibrosis. Patients with 
fibrosis had a longer paced QRS duration (171.7±13.1 
versus 163.5±12.1 ms; P=0.03; Table 3). There was a re-
duction in LVEF in both groups predominantly mediated 
by a decline in LVEDVi (Table 4). The decline in LVEF was 
greater in those with fibrosis due to a concomitant in-
crease in LVESVi, which was not seen in those without fi-
brosis (LVEF: −12.3±7.9% versus −6.7±6.2%, P=0.012; 
LVESVi: 8.0±10.4 versus −0.6±7.3 mL/m2, P=0.008; 
Figure  3; Table  4). Patients with fibrosis had a statis-
tically significant increase in mechanical dyssynchrony 
index from baseline (97.6±31.2 versus 83.7±29.7 ms; 
P=0.03), which was not seen in those without fibrosis. 
The presence of LGE was an independent predictor of 
the percentage change in LVESVi after multivariate ad-
justment (Table IV in the Data Supplement). There was 
no statistically significant difference in the absolute and 
percentage of LGE mass (5SD) between baseline and 
6-month follow-up (3.7±4.1 versus 3.6±3.6 g, P=0.99 
and 5.0±5.4% versus 4.6±4.6%, P=0.52, respectively).
Ten patients (20%) had an LVEF of <35% at follow-
up and would potentially be eligible for a CRT upgrade 
according to international guidelines.1,19 At baseline, all 
these patients had an evidence of myocardial fibrosis 
with mean LVEF of 47.7±5.1%. Six patients had a his-
tory of MI, 2 patients had an ischemic pattern of fibrosis 
with no history of MI, and 2 patients had a nonischemic 
pattern of fibrosis. On receiver operator characteristic 
analysis, the area under the curve of fibrosis by 5 SD (g) 
at baseline to predict LVEF<35% at 6 months was 0.90 
(P<0.0001 [95% CI, 0.78–0.97]; Figure I in the Data 
Supplement). By Youden index, the optimal cutoff was 
>1.1 g fibrosis, which had 90% sensitivity and 70% 
specificity to predict future eligibility for CRT upgrade.
NT-proBNP remained unchanged at follow-up in pa-
tients with fibrosis but decreased in those without fi-
brosis (Table 4). Patients with fibrosis did not experience 
a statistically significant improvement in the New York 
Heart Association class or EuroQoL-5D visual analogue 
scale scores following pacemaker implantation, where-
as those without fibrosis had statistically significant 
improvements in the New York Heart Association class 
(Figure 4) and EuroQoL-5D visual analogue scale scores.






Male sex 9 (56%) 15 (83%) 0.09
Age, y 64.2±12.6 74.2±5.6 0.008
BMI, kg/m2 29.5±6.1 29.2±6.0 0.93
Systolic BP, mm Hg 141.4±20.1 138.3±16.6 0.63
Diastolic BP, mm Hg 84.8±10.4 78.8±7.1 0.05
Medical history
 Diabetes 2 (13%) 2 (11%) 0.57
 Hypertension 7 (44%) 5 (28%) 0.33
 History of MI 0 10 (56%) <0.001
 Paroxysmal AF 2 (13%) 5 (28%) 0.25
Baseline medications
 ACE inhibitor 4 (25%) 12 (67%) 0.02
 ARB 3 (19%) 2 (11%) 0.44
 β-Blocker 6 (38%) 11 (61%) 0.15
Device and ECG data
 Ventricular pacing burden, % 1.3 (0.5–4.5) 0.2 (0.2–0.5) 0.001
  Programmed pacing rate for 
scan, bpm
80 (70–85) 80 (80–80) 0.60
 Intrinsic QRS duration, ms 88 (79–96) 93 (86–108) 0.21






 LVEDVi, mL/m2 65.6±12.4 77.5±13.8 0.01
 LVESVi, mL/m2 29.5±9.8 37.6±11.4 0.03
 LVEF, % 56.0±6.2 52.2±8.0 0.13
 Ischemic LGE NA 11 (61%) NA
 Nonischemic LGE NA 7 (39%) NA
 LGE 5SD, percentage of LV NA 8.6±9.9 NA
 MDI, ms 61.3±17.4 81.3±17.6 0.002
Values are mean±SD, median (interquartile range), or n (%). ACE indicates 
angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor 
blocker; BMI, body mass index; BP, blood pressure; CMR, cardiovascular mag-
netic resonance; LGE, late gadolinium enhancement; LV, left ventricle; LVEDVi, 
left ventricular end-diastolic volume index; LVEF, left ventricular ejection frac-
tion; LVESVi, left ventricular end-systolic volume index; MDI, mechanical dys-
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Device Parameters
There were no adverse clinical events in either study. 
In study 1, there were no changes in device variables 
(Table V in the Data Supplement). In study 2, there were 
small changes in ventricular lead impedance (722±170 
versus 704±150 Ω; P=0.006) and ventricular lead pac-
ing capture threshold (0.72±0.26 versus 0.78±0.25 V; 
P=0.005) following the CMR scan.
DISCUSSION
We have demonstrated that the presence of fibrosis is 
associated with acute and medium-term reduction in 
cardiac function following RV pacing with greater electri-
cal and mechanical dyssynchrony and LV remodeling in 
those with fibrosis. We have also shown that the symp-
tomatic and neurohormonal response, as evaluated by 
NT-proBNP, to pacemaker implantation in patients with 
atrioventricular block is reduced in those with fibrosis. 
Given that fibrosis can be identified before device implan-
tation, it has a potential role in identifying those at risk of 
LV dysfunction and future heart failure, offering a poten-
tial selection criterion for an optimized pacing strategy.
LV dysfunction is common in patients with pacemak-
ers with prevalence as high as 30%.20 The mechanisms 
underlying LV dysfunction in pacemaker recipients are 
incompletely understood and likely involve complex 
Table 2. Cardiovascular Magnetic Resonance Data During AOO and DOO Pacing Modes
Characteristic
No fibrosis (n=16) Fibrosis (n=18)
AOO DOO P value AOO DOO P value
LVEDVi, mL/m2 65.6±12.5 66.0±12.8 0.67 77.5±13.8 78.8±13.4 0.34
LVESVi, mL/m2 29.5±9.8 31.6±8.9 0.003 37.6±11.4 43.0±12.3 <0.001
LVEF, % 56.0±6.2 52.9±5.4 <0.001 52.2±8.0 46.5±9.1 <0.001
MDI, ms 61.3±17.4 71.0±25.0 0.07 81.3±17.6 88.8±21.2 0.04
Values are mean±SD. AOO indicates atrial asynchronous pacing; DOO, dual-chamber asynchronous pacing; LVEDVi, left ventricular 
end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume index; and MDI, mechanical 
dyssynchrony index.
Figure 3. Absolute change in ventricular volumes and function before and after ventricular pacing.
Values are mean±SE. Absolute changes between those with (blue bars) and without (red bars) myocardial fibrosis. Study 1 (left): immediate change between atrial 
asynchronous and dual chamber asynchronous pacing modes in patients with preserved atrioventricular (AV) conduction. Study 2 (right): change from baseline 
(before pacemaker) to 6 mo follow-up in patients implanted with permanent pacemakers for AV block. LVEDVi indicates left ventricular end-diastolic volume index; 
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interactions between factors, such as pacing burden 
and paced QRS duration, and the underlying myocardial 
substrate. The fact that LV function can be improved by 
reducing the burden of RV pacing, through reprogram-
ming or upgrading to CRT in those with unavoidable 
RV pacing, suggests that pacing-induced dyssynchrony 
is a key driver of LV remodeling and dysfunction.21,22 
Furthermore, certain patient populations, such as those 
with preexisting heart failure or previous MI, may be at 
greater risk of developing LV dysfunction or heart failure 
after pacemaker implantation.7,9,23 Upfront physiological 
(CRT or His bundle) pacing may avoid pacing-induced LV 
dysfunction but comes with higher financial costs and 
greater risks of complications. Indeed current guidelines 
do not routinely recommend the use of physiological 
pacing in those with normal or mildly reduced LVEF.1,12 
Given that up to a fifth of patients with preserved LVEF 
develop heart failure or have a decline in LVEF with long-
term RV pacing, and the risk may be the greatest within 
the first 6 months, there is a need for better identifica-
tion of those at risk before pacemaker implantation.3,6,7
Detrimental Effects of the Combination 
of Fibrosis and RV Pacing
We have shown that patients with fibrosis had a greater 
increase in LVESVi and greater decline in LVEF than pa-
tients without fibrosis after RV pacing (Figure 3). Com-
pared with intrinsic atrioventricular conduction, the ini-
tiation of RV pacing was associated with acute increases 
in LVESVi and a fall in LVEF. The immediacy of this change 
likely reflects the acute dyssynchrony induced by RV api-
cal pacing. These changes were more pronounced in pa-
tients with underlying myocardial fibrosis. Medium term, 
those with fibrosis, experienced a greater decline in LVEF 
through an increase in LVESVi and a reduction in LVEDVi 
than those without fibrosis. Interestingly those without 
fibrosis showed no change in LVESVi but also experi-
enced a decline in LVEDVi. We postulate that changes in 
LVEF due to LVEDVi can be accounted for by differences 
in heart rate and subsequent LV filling time between 
baseline and follow-up scans. However medium-term 
changes in LVESVi only occurred in those with fibrosis 
and may reflect not only pacing-induced dyssynchrony 
but also adverse remodeling.
The interaction between differing etiologies of myo-
cardial fibrosis and the susceptibility to pacing-induced 
LV dysfunction in individuals requires larger scale stud-
ies. This may particularly be the case in those with non-
ischemic pattern of LGE where the mechanisms leading 
to fibrosis are unclear.
Clinical Implications
Patients with myocardial fibrosis in this study showed 
no improvements in either functional class or quality 






Male sex 12 (63%) 28 (90%) 0.02
Age, y 77.3±9.9 80.9±8.5 0.17
BMI, kg/m2 22.7±4.2 25.3±4.2 0.02
Systolic BP, mm Hg 150.0±23.2 149.5±19.9 0.94
Diastolic BP, mm Hg 74.0±11.6 75.4±10.4 0.90
Medical history
 Atrial fibrillation 2 (10%) 12 (39%) 0.03
 Diabetes 4 (21%) 14 (45%) 0.09
 Hypertension 12 (63%) 21 (68%) 0.74
 History of MI 0 11 (35%) 0.003
 Previous CABG 0 10 (32%) 0.006
NYHA functional class
 I 6 (32%) 8 (26%)  
 II 11 (58%) 17 (55%) 0.69
 III 2 (10%) 6 (19%)  
Baseline medications, n (%)
 ACE inhibitor 7 (37%) 11 (35%) 0.92
 ARB 2 (10%) 10 (32%) 0.08
 β-Blocker 0 6 (19%) 0.04
ECG data
 Baseline heart rate, bpm 50.5±15.3 56.4±14.5 0.44
 Native QRS duration, ms 115.7±29.4 111.4±21.0 0.92
Biomarkers






 LVEDVi, mL/m2 87.8±21.0 90.3±18.3 0.42
 LVESVi, mL/m2 34.9±9.3 40.9±13.7 0.10
 LVEF, % 60.2±5.4 55.5±7.9 0.03
 LV mass index, g/m2 51.7±17.4 55.8±17.0 0.23
 Ischemic LGE NA 14 (45%) NA
 Nonischemic LGE NA 17 (55%) NA
 LGE 5SD, percentage of LV NA 5.1±5.3 NA
 MDI, ms 70.3±29.1 83.7±29.7 0.08
Pacing and ECG data at follow-up
 Ventricular pacing burden, % 96 (27–99) 85 (29–99) 0.71
 Paced QRS duration, ms 163.5±12.1 171.7±13.1 0.03







Pacing mode for scan
 DOO 17 (90%) 22 (71%) 0.13
 VOO 2 (10%) 9 (29%)  
  Programmed pacing rate for 
scan, bpm
80 (80–100) 80 (80–80) 0.18
Values are mean±SD, median (interquartile range), or n (%). ACE indicates an-
giotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass 
index; BP, blood pressure; CABG, coronary artery bypass grafting; CMR, cardiovas-
cular magnetic resonance; DOO, dual-chamber asynchronous pacing; LGE, late 
gadolinium enhancement; LV, left ventricle; LVEDVi, left ventricular end-diastolic 
volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-
systolic volume index; MDI, mechanical dyssynchrony index; MI, myocardial infarc-
tion; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart 
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of life after pacemaker implantation in contrast to 
those without fibrosis. These findings suggest that the 
observed changes in cardiac function may be clinically 
significant and may, in part, contribute to the lack of 
improvement in quality of life and functional capacity. 
Larger studies with longer follow-up are needed to 
establish whether RV pacing in patients with myocar-
dial fibrosis is associated with other clinical end points 
such as heart failure hospitalization and cardiovascu-
lar mortality.
Table 4. CMR, NYHA Class, and Quality of Life Data Before and After Pacemaker Implantation
Characteristic
No fibrosis (n=19) Fibrosis (n=31)
Pre-PM Post-PM P value Pre-PM Post-PM P value
CMR data
 LVEDVi, mL/m2 87.8±21.0 73.1±14.3 <0.001 90.3±18.3 83.2±20.6 0.007
 LVESVi, mL/m2 34.9±9.3 34.3±9.3 0.71 40.9±13.7 48.9±20.9 0.001
 LVEF, % 60.2±5.4 53.5±6.8 <0.001 55.5±7.9 43.2±11.7 <0.001
 MDI, ms 70.3±29.1 80.8±21.6 0.15 83.7±29.7 97.6±31.2 0.03
NYHA class
 I 6 (32%) 14 (74%)  8 (26%) 10 (32%)  
 II 11 (58%) 5 (26%) 0.02 17 (55%) 15 (49%) 0.84
 III 2 (10%) 0  6 (19%) 6 (19%)  
Biomarkers
 NT-proBNP, pg/mL* 451 (131–736) 229 (380–433) 0.01 1304 (417–2282) 1069 (241–4990) 0.18
Quality of life
 EuroQoL-5D index 0.85±0.13 0.85±0.18 0.89 0.72±0.27 0.79±0.17 0.33
 EuroQoL-5D VAS 70±15 78±16 0.01 61±22 66±18 0.21
Values are mean±SD, median (interquartile range), or n (%). CMR indicates cardiovascular magnetic resonance; LVEDVi, left ventricu-
lar end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume index; MDI, mechanical 
dyssynchrony index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PM, pacemaker; and 
VAS, visual analogue scale.
*n=29 in fibrosis group as follow-up bloods not available in 2 patients.
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Direct comparison of our findings to outcomes of ex-
isting clinical trials is challenging due to different study 
populations, lack of reporting of all echocardiographic 
findings, and different outcome measures.8–11 Further-
more, baseline and follow-up imaging was performed 
at different time points between studies, and the inter-
action between heart rate, LVEDV, and LVEF in patients 
who are profoundly bradycardic potentially makes 
these volumetric parameters poor for risk stratification 
preimplantation.
Up to a fifth of patients develop new-onset heart 
failure or have a decline in LVEF after RV pacing with 
the highest risk in the first 6 months.3,6,7 In our study, 10 
patients (20%) had an LVEF of <35% at 6-month fol-
low-up. Despite this, studies of upfront CRT in unselect-
ed patients with a high burden of RV pacing have failed 
to provide clarity. Although in BLOCK-HF, upfront CRT 
was associated with improved outcomes, the compos-
ite end point combined clinical and echocardiographic 
outcomes in a mixed population, some of whom were 
indicated for CRT.9 In contrast, studies in patients with 
mostly preserved LV function have shown neutral re-
sults.11 Therefore, there remains a need for better iden-
tification of those at risk of heart failure before pace-
maker implantation. The use of CMR upfront enables 
detection of myocardial fibrosis before pacemaker im-
plantation. In our study, myocardial fibrosis was present 
in all patients (n=10) who had an LVEF<35% at follow-
up who would be eligible for upgrade to CRT. There-
fore, the presence of myocardial fibrosis may be an ad-
ditive risk factor for development of heart failure after 
RV pacing. Whether long-term clinical outcomes can be 
improved in those with fibrosis by interventions such as 
upfront CRT, His bundle pacing, or changes in medical 
therapy and the cost effectiveness of preimplantation 
CMR needs to be established.
Limitations
In both studies, there were statistically significant dif-
ferences in baseline clinical and imaging characteris-
tics between those with and without fibrosis, which 
could have influenced intergroup comparisons, and 
larger studies are warranted to evaluate the impact 
of these individual parameters on LV function over 
the longer term.
In study 1, shortening of the atrioventricular delay 
to encourage RV pacing could have contributed to the 
observed changes in LVESVi. However, programming of 
atrioventricular delay was independent of fibrosis status 
allowing comparison between groups.
In study 2, the type of pacemaker and device pro-
gramming were managed by the patient’s clinical team. 
However, clinical teams were blinded to the LGE sta-
tus minimizing differences in pacing programming 
between groups. All patients were scanned in an MRI 
conditional pacing mode mandating ventricular pacing 
at follow-up to avoid inadvertent inhibition of pacing 
and to ensure consistency across patients. In patients 
with a low RV pacing burden, acute dyssynchrony may 
have been induced and altered LV function. However, 
the median RV pacing burden was >80% at the pres-
can check in those with and without fibrosis, making 
RV pacing in the scanner unlikely to account for the 
observed differences between the groups.
Neither study was powered to compare differing 
etiology, degree, or locations of myocardial fibrosis. 
The influence of quantity and location of fibrosis on 
RV pacing-induced LV dysfunction needs to be ex-
plored in future studies.
Conclusions
Myocardial fibrosis identified by CMR LGE is associated 
with immediate- and medium-term impairment in LV 
function in patients exposed to RV pacing. Myocardial 
fibrosis may represent a risk factor that could be used 
prospectively to identify patients susceptible to the det-
rimental effects of RV pacing. Further work is needed 
to identify whether patients with fibrosis benefit from 
alternative pacing strategies or medical therapies ap-
plied at the time of the initial implant.
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